CN111513155A - Composition for preventing and treating lipid metabolism disorder - Google Patents

Composition for preventing and treating lipid metabolism disorder Download PDF

Info

Publication number
CN111513155A
CN111513155A CN202010436353.1A CN202010436353A CN111513155A CN 111513155 A CN111513155 A CN 111513155A CN 202010436353 A CN202010436353 A CN 202010436353A CN 111513155 A CN111513155 A CN 111513155A
Authority
CN
China
Prior art keywords
group
tea
composition
liver
lipid metabolism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010436353.1A
Other languages
Chinese (zh)
Other versions
CN111513155B (en
Inventor
杨兴鑫
俞捷
李静平
穆健康
顾雯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunnan University of Traditional Chinese Medicine TCM
Original Assignee
Yunnan University of Traditional Chinese Medicine TCM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yunnan University of Traditional Chinese Medicine TCM filed Critical Yunnan University of Traditional Chinese Medicine TCM
Priority to CN202010436353.1A priority Critical patent/CN111513155B/en
Publication of CN111513155A publication Critical patent/CN111513155A/en
Application granted granted Critical
Publication of CN111513155B publication Critical patent/CN111513155B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/06—Treating tea before extraction; Preparations produced thereby
    • A23F3/14—Tea preparations, e.g. using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/285—Aucklandia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention provides a health tea for preventing lipid metabolism disorder, which is prepared from the following raw materials: 1-20g of rhizoma polygonati, 1-20g of angelica, 1-20g of pseudo-ginseng, 1-10g of elecampane, 1-10g of poria cocos, 1-10g of red yeast rice and 1-20g of Pu' er tea. The health tea has reasonable compatibility, and can effectively prevent and treat symptoms related to lipid metabolism disorder.

Description

Composition for preventing and treating lipid metabolism disorder
Technical Field
The application relates to health-care tea, in particular to a composition for preventing and treating lipid metabolism disorder.
Background
Abnormal lipid metabolism is usually associated with excessive appetite, fatty taste, fatigue, emotional disorder, congenital deficiency, and other diseases, which are caused by liver depression, spleen deficiency, kidney qi deficiency, phlegm stagnation and blood stasis. The disease is localized in the liver, involving the spleen, stomach, kidney and other viscera, and is marked by deficiency of the origin, excess of the spleen and kidney, and phlegm-turbidity and blood stasis (in the Chinese materia Medica, 2016, 34 (11): 2586-2589).
Although similar compositions exist in the prior art, for example, CN200810058332 discloses a pseudo-ginseng flower and leaf Pu' er tea, which comprises 50-80% by weight of tea leaves, 10% by weight of pseudo-ginseng flowers and 10-40% by weight of pseudo-ginseng flower and leaves, and has good metabolism effects on fat removal, weight reduction, alcoholic liver and fatty liver. CN201310597025 discloses a composition prepared from the following raw materials in parts by weight: corydalis saxicola bunting, rhizoma picrorhizae, pseudo-ginseng, salvia miltiorrhiza, radix puerariae, rhizoma atractylodis macrocephalae, radix paeoniae alba, poria cocos, radix bupleuri, angelica sinensis, lotus leaves, semen coicis, semen benincasae, rhizoma phragmitis, platycodon grandiflorum, semen lepidii, folium eriobotryae, fritillaria cirrhosa, fructus lycii, semen cassiae, rhizoma alismatis, peach kernels and folium mori, the fat deposition of liver cells is relieved, the liver function is improved, and the liver index is reduced, so that the liver cancer treating composition has an obvious treatment. However, the prior art composition has unsatisfactory effect or slightly excessive medicinal taste, is not suitable for practical application in production and life, and thus is not widely used.
Disclosure of Invention
In the invention, the formula consists of 7 substances of rhizoma polygonati, angelica, pseudo-ginseng, elecampane, poria cocos, red yeast rice and Pu' er tea, and the substances are both homologous in medicine and food (can be used as medicinal materials and food). In the formula, the Chinese rhubarb has the effects of tonifying qi and yin, strengthening spleen, moistening lung and tonifying kidney, and enters spleen, lung and kidney channels; the angelica has the functions of enriching blood, activating blood, regulating menstruation, relieving pain and relaxing bowel, is an essential medicine for enriching blood, activating blood and removing stasis, and belongs to the liver, heart and spleen channels, the pseudo-ginseng has the functions of removing blood stasis, stopping bleeding, activating blood and relieving pain and belongs to the liver and stomach channels, and the functions of enriching blood, activating blood and removing stasis are realized by the compatibility of the angelica and the stomach; aucklandia root, radix aucklandiae has the actions of moving qi and soothing liver, regulating middle energizer and relieving stagnation, and enters spleen, stomach, liver and lung meridians; the tuckahoe has the effects of promoting the subsidence of swelling by water, excreting dampness, strengthening the spleen and calming the heart, and enters the channels of the heart, the lung, the spleen and the kidney, and the tuckahoe matched with the formula is beneficial to eliminating turbid phlegm and damp evil out of the body. Therefore, the substances in the formula can effectively aim at the pathogenesis of lipid metabolism disorder. In addition, modern researches show that the red yeast rice and the Pu ' er tea have pharmacological activity for obviously regulating lipid metabolism disorder (doctor's academic paper of Zhejiang university, 2012; Master's academic paper of Anhui medical university, 2017), and the two substances are combined in the formula, so that the function of the formula for regulating lipid metabolism disorder can be further enhanced. Therefore, by soothing the liver, strengthening the spleen, eliminating dampness and removing blood stasis, the composition can effectively prevent and treat symptoms related to lipid metabolism disorder, and can be used for developing medicaments, health-care products and functional foods for preventing and treating the lipid metabolism disorder.
Specifically, the invention provides health-care tea for preventing lipid metabolism abnormality, which is prepared from the following raw materials: 1-20g of rhizoma polygonati, 1-20g of angelica, 1-20g of pseudo-ginseng, 1-10g of elecampane, 1-10g of poria cocos, 1-10g of red yeast rice and 1-20g of Pu' er tea.
The health tea is prepared from the following raw materials: 1-10g of rhizoma polygonati, 1-10g of angelica, 1-10g of pseudo-ginseng, 1-5g of elecampane, 1-5g of poria cocos, 1-5g of red yeast rice and 1-10g of Pu' er tea.
The health tea is prepared from the following raw materials: 1-5g of rhizoma polygonati, 1-5g of angelica, 1-5g of pseudo-ginseng, 1-4g of elecampane, 1-4g of poria cocos, 1-4g of red yeast rice and 1-5g of Pu' er tea.
The health tea is prepared from the following raw materials: 2-4g of rhizoma polygonati, 2-4g of angelica, 2-4g of pseudo-ginseng, 1-3g of elecampane, 1-3g of poria cocos, 1-3g of red yeast rice and 2-4g of Pu' er tea.
The health tea is prepared from the following raw materials: 3g of rhizoma polygonati, 3g of angelica, 3g of pseudo-ginseng, 2g of elecampane, 2g of poria cocos, 2g of red yeast rice and 3g of Pu' er tea.
The invention also provides a composition for preventing and treating lipid metabolism disorder, which comprises the following raw material medicines: 1-20g of rhizoma polygonati, 1-20g of angelica, 1-20g of pseudo-ginseng, 1-10g of elecampane, 1-10g of poria cocos, 1-10g of red yeast rice and 1-20g of Pu' er tea.
Further, a composition for treating lipid metabolism disorder is provided, and the raw material medicines comprise: 1-10g of rhizoma polygonati, 1-10g of angelica, 1-10g of pseudo-ginseng, 1-5g of elecampane, 1-5g of poria cocos, 1-5g of red yeast rice and 1-10g of Pu' er tea.
Further, a composition for treating lipid metabolism disorder is provided, and the raw material medicines comprise: 1-5g of rhizoma polygonati, 1-5g of angelica, 1-5g of pseudo-ginseng, 1-4g of elecampane, 1-4g of poria cocos, 1-4g of red yeast rice and 1-5g of Pu' er tea.
Further, a composition for treating lipid metabolism disorder is provided, and the raw material medicines comprise: 2-4g of rhizoma polygonati, 2-4g of angelica, 2-4g of pseudo-ginseng, 1-3g of elecampane, 1-3g of poria cocos, 1-3g of red yeast rice and 2-4g of Pu' er tea.
Further, a composition for treating lipid metabolism disorder is provided, and the raw material medicines comprise: 3g of rhizoma polygonati, 3g of angelica, 3g of pseudo-ginseng, 2g of elecampane, 2g of poria cocos, 2g of red yeast rice and 3g of Pu' er tea.
The preparation method of the health tea comprises the following steps:
pulverizing the raw materials into fine powder, reflux-extracting with 12 times of 95% ethanol at 90 deg.C, reflux-extracting with 12 times of 70% ethanol for 2 hr each time, mixing the extractive solutions, concentrating at 65 deg.C and 100 deg.C under reduced pressure, recovering ethanol, and making into lyophilized powder. It is administered by infusing with water.
The preparation method of the composition comprises the following steps:
pulverizing the raw materials into fine powder, performing reflux extraction with 12 times of 95% ethanol at 90 deg.C, performing reflux extraction with 12 times of 70% ethanol for 2 hr each time, mixing the two extractive solutions, concentrating at 65 deg.C and 100 deg.C under reduced pressure, recovering ethanol, and making into pharmaceutically acceptable preparation by conventional method.
The preparation is selected from decoction, tablet, capsule, pill, dripping pill, granule, and powder.
Drawings
FIG. 1 the food intake of rats in each group during the experiment (. SP <0.05,. SP <0.01,. SP <0.001, compared to the normal group)
FIG. 2 weight growth tendency of rats in each group during the experiment
FIG. 3 Effect of the composition on serum TC, TG levels in rats with disturbed lipid metabolism (. SP <0.05,. SP <0.01,. SP <0.001, compared to the model group)
FIG. 4 liver histomorphology (oil Red O staining, X200) of rats in each group
A, normal group B, model group C, low dose group D, medium dose group E, high dose group F, resveratrol group
FIG. 5 immunohistochemical analysis of rat hepatocytes (tune,. times.200)
A, normal group B, model group C, low dose group D, medium dose group E, high dose group F, resveratrol group
FIG. 6 Effect of the composition on high fat-induced lipid metabolism disorder rat liver TG, TC, LDL-C and HDL-C
P <0.05 compared to model group; p < 0.01; p <0.001
FIG. 7 Effect of the composition on MDA and GSH in rat liver with high fat-induced lipid metabolism disorder (P < 0.05;. P < 0.01;. P <0.001, compared to model group)
FIG. 8 Effect of the composition on the levels of mitochondria Complex I, Camplex II, ATP in rat liver with high lipid-induced lipid metabolism disorders (P < 0.05;. P < 0.01;. P <0.001, compared to model group)
FIG. 9 Effect of the composition on the levels of GSH, SOD and MDA in liver mitochondria of rats with high lipid-induced lipid metabolism disorders (P < 0.05; P < 0.01; P < 0.001; in comparison with the model group)
FIG. 10 food intake of rats in each group during the experiment
FIG. 11 weight growth trend of rats in each group during the experiment
FIG. 12 Effect of composition, Red Rice and Pu her tea on serum TG and TC content in NAFLD rats (P <0.05, P <0.01, P <0.001 for model group; P <0.05, # P <0.01, # P <0.001 for composition group)
FIG. 13 liver histomorphology (oil red O staining, X200) of rats in each group
A, normal group; b, model group; c, resveratrol group; d, red yeast rice group; e, Pu' er tea group; f, composition group
FIG. 14 immunohistochemical analysis of rat hepatocytes (tune,. times.200)
A, normal group; b, model group; c, resveratrol group; d, red yeast rice group; e, Pu' er tea group; f, composition group
FIG. 15 Effect of composition, Red Rice and Pu her tea on NAFLD rat liver TG, TC, LDL-C and HDL-C (P <0.05, P <0.01, P <0.001 for model group; P <0.05, # P <0.01, # P <0.001 for composition group)
FIG. 16 Effect of the composition, Red Rice and Pu' er tea on high fat induced NAFLD rat liver MDA, GSH (P <0.05, P <0.01, P <0.001 for the model group; P <0.05, # P <0.01, P <0.001 for the composition group)
FIG. 17 effects of composition, Red Rice and Pu' er tea on high lipid-induced NAFLD rat liver mitochondria complexI, complexII, ATP levels (P <0.05, # P <0.01, # P < 0.001; composition group, # P <0.05, # P <0.01, # P <0.001)
Detailed Description
EXAMPLE 1 decoction
(1) Prescription
3g of rhizoma polygonati, 3g of angelica, 3g of pseudo-ginseng, 2g of elecampane, 2g of poria cocos, 2g of red yeast rice and 3g of Pu' er tea.
(2) Preparation of
Pulverizing the above seven medicinal materials, decocting with 8 times of water twice, each for 2 hr, and concentrating.
Example 2 granules
(1) Prescription
3g of rhizoma polygonati, 3g of angelica, 3g of pseudo-ginseng, 2g of elecampane, 2g of poria cocos, 2g of red yeast rice and 3g of Pu' er tea.
(2) Preparation of
Pulverizing the raw materials into fine powder, reflux-extracting with 12 times of 95% ethanol at 90 deg.C, reflux-extracting with 12 times of 70% ethanol for 2 hr each time, mixing the extractive solutions, concentrating under reduced pressure at 65 deg.C and 100 deg.C, recovering ethanol, preparing lyophilized powder, adding sucrose and dextrin, mixing, granulating, and drying.
EXAMPLE 3 clinical trials
1. Method of treatment
The method for treating hyperlipemia by soothing liver, strengthening spleen, eliminating dampness and removing blood stasis is adopted, and the composition is given as follows: 3g of rhizoma polygonati, 3g of angelica, 3g of pseudo-ginseng, 2g of elecampane, 2g of poria cocos, 2g of red yeast rice and 3g of Pu' er tea. 1 dose daily, decocted in water for oral administration, and taken 2 times in the morning and at night. 10 days is 1 course of treatment, and 6 courses of treatment are continued. The follow-up visit was 6 months.
2. Standard of therapeutic effect
The effect is shown: after treatment, the blood fat is reduced to a normal level, and after half a year, the blood fat is not increased after the double-check. The method has the following advantages: after treatment, blood fat is obviously reduced, but the level is slightly higher than the normal level, and the trend of continuous medication is downward. And (4) invalidation: the blood lipid level is slightly reduced, but the blood lipid level tends to increase after half a year of stopping taking the medicine.
3. Results
After being treated by 238 patients with hyperlipidemia and obesity for 6 courses of treatment, the patients with hyperlipidemia have different degrees of curative effect changes in mild, moderate and severe degrees, and the significant efficiency is 67.2%. Meanwhile, the functions of liver and kidney and the routine of hematuria are normal after reexamination, and invalid patients are reexamined after half a year, and the rest blood fat has no phenomenon of rising and rebounding.
TABLE 1238 treatment efficacy in patients (% of cases)
Figure BDA0002502419200000031
Figure BDA0002502419200000041
EXAMPLE 4 intervention of the composition on rats with lipid metabolism disorders induced by high-fat diet
First, experimental materials and methods
(I) test materials
1 materials of the experiment
All the materials are purchased from the medicinal material wholesale market of Kunming snail bay, and certificate specimens are all stored in the key laboratory for preventing and treating metabolic diseases in the Kunming market.
Positive control resveratrol was purchased from Doppel Biotechnology, Inc.
2 laboratory animals
Clean-grade SPraque-Dawley healthy male rats at 8 weeks 60, with a weight of 180 + -20g, purchased from WUDUDUDUDUDO, Inc., quality certification number: SCXK (Chuan) 2015-030. The experimental conditions and the method are qualified by the ethical examination of the animal experiment center of the Yunnan college of traditional Chinese medicine, and the animal ethical examination document number is as follows: r-062014012. Prior to the experiment, all rats were acclimatized for 1 week, during which time the animals were fed ad libitum with free access to water. Keeping the feeding room quiet, keeping the indoor temperature at 23-25 ℃, keeping the humidity at 55-75%, lighting by a fluorescent lamp, and keeping the lighting for 12 hours and dark for 12 hours in 24 hours every day.
3 Experimental reagent
Experimental animal feed (Suzhou double lion experimental animal feed science and technology limited)
Resveratrol (Chengdu Philide biotechnology limited)
Low-density lipoprotein (LDL-C) test box (Nanjing institute of bioengineering)
Malondialdehyde (MDA) test box (Nanjing institute of bioengineering)
Superoxide dismutase (SOD) test box (Nanjing institute of bioengineering)
Triglyceride (TG) test box (Nanjing institute of bioengineering)
Total cholesterol (T-CHO) test box (Nanjing institute of biological engineering)
High density lipoprotein (HDL-C) test box (Nanjing institute of bioengineering)
Glutathione peroxidase (GSH) test box (Nanjing institute of bioengineering)
ATP enzyme test box (Nanjing institute of bioengineering)
BCA protein concentration determination kit (Biyuntian biotechnology research institute)
Rat mitochondrial respiratory chain complex I test box (Shanghai Jiwei Biotech Co., Ltd.)
Rat mitochondrial respiratory chain complex II test box (Shanghai Jiwei Biotech Co., Ltd.)
Sucrose (Tianjin City wind boat chemical reagent science and technology Co., Ltd.)
Tris (Beijing Bootoda science and technology Co., Ltd.)
Mannitol (Biosharp science and technology Co., Ltd.)
EDTA (Biosharp technologies Co., Ltd.)
EGTA (Biosharp technologies Co., Ltd.)
Absolute ethyl alcohol (national medicine group chemical reagent Co., Ltd.)
4 laboratory instruments
BS224 electronic balance (d 0.0001g) (Beijing Series Instrument systems, Inc.)
Vortex oscillator (LAB-BLOGEN Beijie science and technology VTX-E)
JJ1000 type precision electronic balance (d is 0.02g) (double jie test instrument factory)
T-5000 type electronic balance (d ═ 1g) (commonly-known Shuangjie tester)
DY 89-II TYPE ELECTRIC GLASS HOURIZER (Ningbo Xinzhi BIOLOGICAL SCHOOL GYN Co., Ltd.)
Enzyme mark analyzer (DNM-9602G) (Beijing Pulang New technology Co., Ltd.)
Ultraviolet spectrophotometer (756 type) (Shanghai spectrometer Co., Ltd.)
High speed desk type refrigerated centrifuge (TJL-20M) (Changshan instrument centrifuge Co., Ltd.)
OSB-2100 type water-bath (Shanghai Ailang apparatus Co., Ltd.)
N-1100 type rotary evaporator (Shanghai Ailang instrument Co., Ltd.)
SHZ-DIII type circulating water vacuum pump (Steuer City Zenhua Instrument Limited liability company)
DL-5-B type centrifuge (Shanghai' an pavilion scientific instrument factory)
Water purification machine (Milli-Q Academic A10 ultrapure water system) (MilliPore company, USA)
Ultrapure Water System (Milli-Q Reference) (MilliPore, USA)
Ultra-low temperature refrigerator (American Thermo company)
SX-500 type steam sterilizer (TOMY KOGYO CO LTD Co., Japan)
HHS type electric heating constant temperature water bath (Shanghai Boxun industry Co., Ltd.)
Ultrasonic cleaning machine (14-1275) (Ningbo Xinzhi Biotechnology Co., Ltd.)
80 ℃ refrigerator 8920(834747-328) (Thermo scientific)
DY 89-II TYPE ELECTRIC GLASS HOURIZER (Ningbo Xinzhi BIOLOGICAL SCHOOL GYN Co., Ltd.)
SPectrama Plus plate reader (Molecular Devices, USA)
(II) Experimental method
1 preparing the extract of the composition
Grinding the composition into fine powder, and mixing the components in a ratio of 3: 3: 3: 2: 2: 2: 3, mixing, performing reflux extraction with 12 times of 95% ethanol at 90 ℃, performing reflux extraction with 12 times of 70% ethanol for 2h each time, combining the two extracting solutions, performing concentration at 65 ℃ and 100 rpm, recovering ethanol under reduced pressure, and preparing the freeze-dried powder.
2 replication, grouping and administration of lipid metabolism disorder rat model
The 60 clean grade SPraque-Dawley healthy SD male rats were randomly divided into 6 groups of 10, i.e. normal (saline), model (saline), positive (resveratrol), low, medium and high dose groups of composition extracts (grouping and dosing details are shown in table 2); each group of rats was gavaged with 1mL of 250g body weight for 12 weeks 1 time per day. Except for the normal group, each group was fed with high fat diet (basal diet 79%, lard 10%, egg yolk 10%, cholesterol 1%), and during the experiment, the food intake of rats was recorded once a day, the body weight of rats was recorded once a week, and the food intake and body weight of rats per week were calculated for each group.
TABLE 2 rat grouping and dosing
Figure BDA0002502419200000051
Figure BDA0002502419200000061
3 sample Collection
After the last administration in 12 weeks, the experimental rats were fasted for 12h, and the rats were anesthetized with pentobarbital sodium, after blood sampling, serum was immediately separated by centrifugation (3500r ∙ min-1, 10min), and the desired organs were stored in a refrigerator at-80 ℃ for further use.
4 histopathological Observation
Dyeing with oil red O: the liver is taken, and morphological changes are observed after fixation, dehydration, paraffin embedding, flaking and oil red O staining.
TUNEL detection of hepatocyte apoptosis: reference methods, immunohistochemistry was performed to detect apoptosis.
5 serum biochemical index determination
Detecting the content of total cholesterol TC and triglyceride TG in serum according to the specific steps of the kit specification.
Index of 6 organs
Each organ (liver, spleen, kidney) was dissected and weighed, and the organ index was calculated as (weight g/weight g of organ) x 100%.
7 Biochemical index determination of liver tissue
Collecting 0.1g rat liver, mincing in homogenizing tube (ice bath operation), adding 0.9mL precooled physiological saline, homogenizing 10 times, transferring into 1.5mL centrifuge tube, 4 deg.C, 3000rpm ∙ min-1Centrifuging for 10min, and collecting supernatant. And (3) determining the protein content in the supernatant by using a BCA protein determination kit, adding the reagents in sequence according to the operation of a kit specification, oscillating, fully mixing uniformly, and determining the contents of TC, TG, HDL-C, LDL, MDA and GSH in the supernatant.
8 liver cell mitochondria related index
(1) Hepatocyte mitochondrial isolation
Taking rat liver 0.1g, adding 1mL of precooled mitochondrial separation fluid (0.21M mannitol, 0.07M sucrose, 10mM Tris base, 1mM EDTA, 0.5mM EGTA, pH to 7.4), and homogenizing in ice-water bath; transferring the tissue homogenate to a centrifuge tube, centrifuging at 4 ℃ and 1000 Xg for 10min, discarding the precipitate, transferring the supernatant to another centrifuge tube, centrifuging at 4 ℃ and 10000 Xg for 10min, and obtaining the precipitate, namely the hepatocyte mitochondria.
(2) Determination of MDA, SOD, GSH, ATP synthase and complete I, II in liver cell mitochondria
Taking liver cell mitochondria, adding physiological saline, mixing uniformly to form suspension, and measuring the protein concentration of the mitochondria by using a BCA protein concentration measuring kit; 100 mu L of mitochondrial suspension is taken respectively, according to the operation of the kit specification, SOD activity is determined by an hydroxylamine method, MDA content is determined by a thiobarbituric acid method, GSH and ATP synthase activity is determined by a colorimetric method, and Complex I and II activity is determined by a double-antibody sandwich enzyme-linked immunosorbent assay.
9 statistical processing
Mean ± sd of each group
Figure BDA0002502419200000062
Data were analyzed using SPSS 21.0 statistical software, and between-group comparisons were performed using analysis of variance (One Way-ANOVA), and between groups were performed using the LSD-t test, where P <0.05 was considered as a statistical difference.
Second, experimental results
Effect of composition on weight gain of rats with lipid metabolism disorder induced by high fat
In the experimental process, rats in each group do not die, normally eat and drink water, move freely, have good fur glossiness and quickly respond to external stimulation. From the beginning of the experiment to the end of the experiment at 12 weeks, the results show that the average daily food intake of the rats in each group has no significant difference (figure 1), the rats in each group have a positive growth trend (figure 2), and the weight is normally increased.
(II) influence of composition on TC and TG levels in serum of rat with high fat induced lipid metabolism disorder
As shown in FIG. 3, TG content was significantly increased in the model group (P <0.001) compared to the normal group, indicating that the induction of high-fat diet is very likely to cause serum lipid disorders in rats. Compared with the model group, at the end of the experiment at week 12, the content of TC and TG in the serum of the resveratrol group rat is remarkably reduced (P <0.01 and P <0.001), the content of TG in the high, medium and low dose groups is remarkably reduced (P <0.001), and the content of TC in the high dose group is remarkably reduced (P <0.05) without significant difference. The result shows that the composition extract can regulate the dyslipidemia of the rats with lipid metabolism disorder induced by high-fat feed.
(III) Effect of composition on organ index of rat with lipid metabolism disorder induced by high fat
After 12 weeks of experiment, the liver, kidney and spleen of each group of rats were weighed, and the liver index, spleen index and kidney index of each group were calculated (table 2). The results show that the liver indexes of other groups are significantly different (P is less than 0.05, P is less than 0.01, and P is less than 0.001) compared with the normal group, which indicates that the liver is enlarged after the high-fat feed is fed for 12 weeks; the spleen index and kidney index were not significantly different (P <0.05) from those of the normal group, and it is noted that the spleen index and kidney index were lower in the model group than those of the other groups, indicating that high fat diet may cause some damage to the spleen and kidney, and that the administration of the drug alcohol extract could improve the damage. Compared with the model group, except the high-dose group, the liver swelling degree of other administration groups can be reduced, and the compound extract can improve the liver injury of the rat with the high fat-induced lipid metabolism disorder.
TABLE 3 Effect of compositions on organ index of lipid metabolism-disturbed rats: (
Figure BDA0002502419200000071
n＝7)
Figure BDA0002502419200000072
P <0.05, P <0.01, P <0.001, compared to normal; # P <0.05, # P <0.01, # P <0.001, compared to the model group
(IV) Effect of the composition on liver histomorphology of rat with high fat induced lipid metabolism disorder
The liver histomorphometry results of rats in each group showed (fig. 4) that the area percentage of lipid droplets in the normal group rats was 4.27%, the area percentage of lipid droplets in the model group was 55.47%, the area percentage of resveratrol-based lipid droplets was 38.68%, and the percentage of lipid droplets in the compound extract was low, in the medium and high dose groups was 40.82%, 39.21% and 45.17%. The rats in the model group show diffuse hepatocellular edema degeneration, are scattered in a large number of round vacuolated lipid droplets with different sizes and inflammatory cell infiltration in the sink area. The pathological morphology of the liver of the rats interfered by the resveratrol group and the administration group is close to that of the normal control group, a small amount of inflammatory cells infiltrate, and the number of lipid drops is less than that of the model group. The result shows that the composition extract can effectively improve the liver histomorphosis caused by high-fat feed.
The immunohistochemical Tunel apoptosis rate analysis result shows (figure 5) that the liver cell apoptosis rates of the normal group, the model group, the resveratrol group, the low dose group, the medium dose group and the high dose group are respectively 19.76%, 35.00%, 6.23%, 41.26%, 16.98% and 22.72%, which indicates that the medium and high dose groups of the composition extract can relieve cell apoptosis in the process of lipid metabolism disorder and protect liver cells from damage.
(V) Effect of the composition on lipid metabolism disorder rat liver TG, TC, LDL-C and HDL-C
The results in FIG. 6 show that the liver tissues of the model group have significantly increased TC, TG and LDL-C contents (P <0.001) and significantly decreased HDL-C contents (P <0.001), compared with the normal group, indicating that the liver of the rat induced by high fat has significant lipid metabolism disorder. Compared with a model group, TC and TG in the resveratrol group liver tissue are remarkably reduced (P is less than 0.01, P is less than 0.001), HDL-C content is remarkably increased (P is less than 0.001), and LDL-C content has a tendency of reduction without remarkable change, so that the resveratrol group liver lipid abnormality regulating method can regulate high fat induced liver lipid abnormality; after the compound extract with different doses is given, the TC and TG contents in the low, medium and high dose administration groups are reduced remarkably (P is less than 0.001); the LDL-C content of the high-dose administration group is reduced remarkably (P is less than 0.001), and meanwhile, the low-dose and medium-dose administration groups can reduce the LDL-C content to a certain extent without remarkable difference; the HDL-C content in the low, medium and high dose administration groups has a certain rising trend, but no significant difference exists. The results show that the compound extract can better improve the liver lipid abnormality induced by high-fat feed.
(VI) Effect of the composition on MDA and GSH of rat liver with lipid metabolism disorder
As shown in the results of FIG. 7, compared with the normal group, the MDA content in liver mitochondria of the model group rats is remarkably increased (P <0.001), and the GSH activity is remarkably reduced (P <0.05), which indicates that oxidative stress and lipid peroxidation damage exist in the livers of the rats with lipid metabolism disorder. Compared with a model group, after the compound extract is administered, the MDA content in each dose administration group is reduced extremely remarkably (P is less than 0.001), the GHS content in a medium dose administration group is increased extremely remarkably, and low and high dose administration groups are increased to a certain extent but are not changed remarkably. The composition extract can effectively regulate the oxidative stress and lipid peroxidation damage of rats with lipid metabolism disorder, thereby relieving the occurrence of the lipid metabolism disorder.
(VII) Effect of the composition on ATP synthase and Complex I, II in liver mitochondria of rats with lipid metabolism disorder
As can be seen from the results of FIG. 8, Complex I and Comp in liver mitochondria of rat in the model group are compared with those in the normal grouplex II, ATP synthase (Na)+-K+-ATPase, Ca2+-Mg2+ATP enzyme) content is extremely reduced (P <0.001), and the energy metabolism disorder of liver mitochondria of rats with the lipid metabolism disorder is shown. And compared with a model group, the resveratrol remarkably increases Na+-K+-ATPase Activity (P)<0.001), significant difference in Complex II activity (P)<0.05), Ca is increased to some extent2+-Mg2+The activity of ATPase and Complex II is not significantly different, which shows that the ATPase can improve the energy metabolism of rats with lipid metabolism disorder to a certain extent; after the compound alcohol extract with different doses is given, the activity of complete II in liver mitochondria of the low, medium and high dose administration groups is remarkably improved (P is less than 0.001); the low-dose administration group can increase Na to a certain extent+-K+-atpase and complexii activities, but without significant difference; high dosage of Na+-K+-ATPase, Ca2+-Mg2+Trend of ATPase activity, but no significant difference. The result shows that the compound extract can regulate the disturbance of the energy metabolism of the rat with the disorder of the lipid metabolism to a certain extent.
(VIII) influence of composition on MDA, GSH and SOD content in liver mitochondria of rat with lipid metabolism disorder
As shown in the results of FIG. 9, compared with the normal group, the liver mitochondria of the rats in the model group have significantly increased MDA content (P <0.05), significantly reduced GSH content (P <0.05), and somewhat reduced SOD and activity (no significant difference), indicating that the liver mitochondria of the rats with lipid metabolism disorder have oxidative stress and lipid peroxidation damage. Compared with a model group, the resveratrol group obviously reduces the MDA content (P <0.05), obviously improves the GSH (P <0.05) and improves the SOD activity to a certain extent, but has no obvious change, which indicates that the resveratrol group can improve the oxidative stress capability of rats with lipid metabolism disorder to a certain extent; after the composition extract is administered, the MDA content of a low-dose administration group is remarkably reduced (P is less than 0.01), and the MDA content of a medium-dose administration group and a high-dose administration group is reduced to a certain extent but has no remarkable difference; the SOD and GSH activity of the low-dose administration group has a certain rising trend (no obvious change), and the SOD activity of the medium-dose administration group is obviously raised (P is less than 0.01); the activity of the high-dose SOD and GSH is uniformly increased to a fixed extent (without obvious change); the compound extract is shown to be capable of regulating liver mitochondrial function to a certain extent and improving oxidative stress capability of NALFD rat liver.
Example 5 comparative study on the intervention Effect of the composition, Red Rice and Pu her tea on rats with high fat diet induced lipid metabolism disorder
In order to further prove that the composition of the invention obtains more excellent effects of reducing blood fat and regulating lipid metabolism disorder compared with red yeast rice and Pu' er tea, action comparison research is carried out.
First, experimental materials and methods
(I) test materials
1 materials of the experiment
All the materials are purchased from the medicinal material wholesale market of Kunming snail bay, and certificate specimens are all stored in the key laboratory for preventing and treating metabolic diseases in the Kunming market.
Resveratrol, a positive drug, was purchased from Doppel Biotechnology, Inc.
2 laboratory animals
8 week old clean grade Spraque-Dawley healthy male rats 60, body weight 180 + -20g, purchased from WUDUDUDUDO animal Co., Ltd., quality certification number: SCXK (Chuan) 2015-030. The experimental conditions and the method are qualified by the ethical examination of the animal experiment center of the Yunnan college of traditional Chinese medicine, and the animal ethical examination document number is as follows: r-062014012. Prior to the experiment, all rats were acclimatized for 1 week, during which time the animals were fed ad libitum with free access to water. Keeping the feeding room quiet, keeping the indoor temperature at 23-25 ℃, keeping the humidity at 55-75%, lighting by a fluorescent lamp, and keeping the lighting for 12 hours and dark for 12 hours in 24 hours every day.
3 Experimental reagent
Experimental animal feed (Suzhou double lion experimental animal feed science and technology limited)
Resveratrol (Chengdu Philide biotechnology limited)
Low-density lipoprotein (LDL-C) test box (Nanjing institute of bioengineering)
Malondialdehyde (MDA) test box (Nanjing institute of bioengineering)
Superoxide dismutase (SOD) test box (Nanjing institute of bioengineering)
Triglyceride (TG) test box (Nanjing institute of bioengineering)
Total cholesterol (T-CHO) test box (Nanjing institute of biological engineering)
High density lipoprotein (HDL-C) test box (Nanjing institute of bioengineering)
Glutathione peroxidase (GSH) test box (Nanjing institute of bioengineering)
ATP enzyme test box (Nanjing institute of bioengineering)
BCA protein concentration determination kit (Biyuntian biotechnology research institute)
Rat mitochondrial respiratory chain complex I test box (Shanghai Jiwei Biotech Co., Ltd.)
Rat mitochondrial respiratory chain complex II test box (Shanghai Jiwei Biotech Co., Ltd.)
Sucrose (Tianjin City wind boat chemical reagent science and technology Co., Ltd.)
Tris (Beijing Bootoda science and technology Co., Ltd.)
Mannitol (Biosharp science and technology Co., Ltd.)
EDTA (Biosharp technologies Co., Ltd.)
EGTA (Biosharp technologies Co., Ltd.)
Absolute ethyl alcohol (national medicine group chemical reagent Co., Ltd.)
4 laboratory instruments
BS224 electronic balance (d 0.0001g) (Beijing Series Instrument systems, Inc.)
Vortex oscillator (LAB-BLOGEN Beijie science and technology VTX-E)
JJ1000 type precision electronic balance (d is 0.02g) (double jie test instrument factory)
T-5000 type electronic balance (d ═ 1g) (commonly-known Shuangjie tester)
DY 89-II TYPE ELECTRIC GLASS HOURIZER (Ningbo Xinzhi BIOLOGICAL SCHOOL GYN Co., Ltd.)
Enzyme mark analyzer (DNM-9602G) (Beijing Pulang New technology Co., Ltd.)
Ultraviolet spectrophotometer (756 type) (Shanghai spectrometer Co., Ltd.)
High speed desk type refrigerated centrifuge (TJL-20M) (Changshan instrument centrifuge Co., Ltd.)
OSB-2100 type water-bath (Shanghai Ailang apparatus Co., Ltd.)
N-1100 type rotary evaporator (Shanghai Ailang instrument Co., Ltd.)
SHZ-DIII type circulating water vacuum pump (Steuer City Zenhua Instrument Limited liability company)
DL-5-B type centrifuge (Shanghai' an pavilion scientific instrument factory)
Water purifier (Milli-Q Academic A10 ultrapure water system) (Millipore corporation of America)
Ultrapure Water System (Milli-Q Reference) (Millipore corporation, USA)
Ultra-low temperature refrigerator (American Thermo company)
SX-500 type steam sterilizer (TOMY KOGYO CO LTD Co., Japan)
HHS type electric heating constant temperature water bath (Shanghai Boxun industry Co., Ltd.)
Ultrasonic cleaning machine (14-1275) (Ningbo Xinzhi Biotechnology Co., Ltd.)
80 ℃ refrigerator 8920(834747-328) (Thermo scientific)
DY 89-II TYPE ELECTRIC GLASS HOURIZER (Ningbo Xinzhi BIOLOGICAL SCHOOL GYN Co., Ltd.)
SpectraMax Plus plate reader (Molecular Devices, USA)
(II) Experimental method
1 preparation of composition, red yeast rice and Pu' er tea extract
Composition extract (B): grinding the composition into fine powder, and mixing the components in a ratio of 3: 3: 3: 2: 2: 2: 3, mixing, performing reflux extraction with 12 times of 95% ethanol at 90 ℃, performing reflux extraction with 12 times of 70% ethanol for 2h each time, combining the two extracting solutions, performing concentration at 65 ℃ and 100 rpm, recovering ethanol under reduced pressure, and preparing the freeze-dried powder.
Red yeast rice and Pu' er tea extracts: pulverizing red rice and Pu her tea into fine powder, respectively reflux-extracting with 12 times of 95% ethanol at 90 deg.C, reflux-extracting with 12 times of 70% ethanol for 2 hr each time, mixing the two extractive solutions, concentrating at 65 deg.C and 100 deg.C under reduced pressure, recovering ethanol, and making into lyophilized powder.
2NAFLD rat model replication, grouping and dosing
The 60 cleaning grade Spraque-Dawley healthy SD male rats are randomly divided into 6 groups, and 10 rats in each group are a normal group (normal saline), a model group (normal saline), a positive drug group (resveratrol), a composition group, a monascus group and a Pu' er tea group (the grouping and the administration are detailed in Table 4); each group of rats was gavaged with 1mL of 250g body weight for 12 weeks 1 time per day. Except for the normal group, each group was fed with high fat diet (basal diet 79%, lard 10%, egg yolk 10%, cholesterol 1%), and during the experiment, the food intake of rats was recorded once a day, the body weight of rats was recorded once a week, and the food intake and body weight of rats per week were calculated for each group.
TABLE 4 rat grouping and dosing
Figure BDA0002502419200000101
Figure BDA0002502419200000111
3 sample Collection
After the last administration in 12 weeks, the experimental rats were fasted for 12h, and the rats were anesthetized with pentobarbital sodium, after blood sampling, serum was immediately separated by centrifugation (3500r ∙ min-1, 10min), and the desired organs were stored in a refrigerator at-80 ℃ for further use.
4 histopathological Observation
Dyeing with oil red O: the liver is taken, and morphological changes are observed after fixation, dehydration, paraffin embedding, flaking and oil red O staining.
TUNEL detection of hepatocyte apoptosis: reference methods, immunohistochemistry was performed to detect apoptosis.
5 serum biochemical index determination
Detecting the content of total cholesterol TC and triglyceride TG in serum according to the specific steps of the kit specification.
Index of 6 organs
Each organ (liver, spleen, kidney) was dissected and weighed, and the organ index was calculated as (weight g/weight g of organ) x 100%.
7 Biochemical index determination of liver tissue
0.1g of rat liver is cut into pieces in a homogenizing tube (ice bath operation), 0.9mL of precooled physiological saline is added for homogenizing for 10 times, the homogenate is transferred to a 1.5mL centrifuge tube, the centrifugation is carried out for 10min at 4 ℃ and 3000rpm ∙ min < -1 >, and the supernatant is taken for standby. And (3) determining the protein content in the supernatant by using a BCA protein determination kit, adding the reagents in sequence according to the operation of a kit specification, oscillating, fully mixing uniformly, and determining the contents of TC, TG, HDL-C, LDL, MDA and GSH in the supernatant.
8 liver cell mitochondria related index
(1) Hepatocyte mitochondrial isolation
Taking rat liver 0.1g, adding 1mL of precooled mitochondrial separation fluid (0.21M mannitol, 0.07M sucrose, 10mM Tris base, 1mM EDTA, 0.5mM EGTA, pH to 7.4), and homogenizing in ice-water bath; transferring the tissue homogenate to a centrifuge tube, centrifuging at 4 ℃ and 1000 Xg for 10min, discarding the precipitate, transferring the supernatant to another centrifuge tube, centrifuging at 4 ℃ and 10000 Xg for 10min, and obtaining the precipitate, namely the hepatocyte mitochondria.
(2) ATP synthase and complete I, II assay in liver cell mitochondria
Taking liver cell mitochondria, adding physiological saline, mixing uniformly to form suspension, and measuring the protein concentration of the mitochondria by using a BCA protein concentration measuring kit; 100 mu L of mitochondria suspension is taken respectively, the operation is carried out according to the instruction of the kit, the ATP synthase activity is measured by a colorimetric method, and the Complex I and II activity is measured by a double-antibody sandwich method enzyme-linked immunosorbent assay.
9 statistical processing
Mean ± sd of each group
Figure BDA0002502419200000112
Data were analyzed using SPSS 21.0 statistical software, and between-group comparisons were performed using analysis of variance (One Way-ANOVA), and between groups were performed using the LSD-t test, where P <0.05 was considered as a statistical difference.
Second, experimental results
(I) influence of composition, red yeast rice and Pu' er tea on weight gain of high fat-induced NAFLD rats
In the experimental process, rats in each group do not die, normally eat and drink water, move freely, have good fur glossiness and quickly respond to external stimulation. From the beginning of the experiment to the end of the experiment at 12 weeks, the results showed that there was no significant difference in average food intake per week for each group of rats (fig. 10), and each group of rats showed a positive growth trend (fig. 11) and gained weight normally.
(II) influence of composition, red yeast rice and Pu' er tea on serum TC and TG levels of high-fat-induced NAFLD rats
As shown in FIG. 12, TG content was significantly increased (P <0.001) and TC content was significantly increased (P <0.05) in the model group compared to the normal group, indicating that high-fat diet induction caused serum lipid disorders in rats. Compared with the model group, after the experiment in the 12 th week, the content of TC and TG in the serum of the resveratrol group rat is obviously reduced (P is less than 0.05 and less than 0.001), which shows that the resveratrol group rat can regulate and regulate the high fat induced NAFLD rat dyslipidemia; compared with the model group, the content of TG in the red yeast rice group, the Pu 'er tea group and the composition group is remarkably reduced (P is less than 0.001), and the content level of TG in the composition group is remarkably lower than that in the red yeast rice group and the Pu' er tea group (P is less than 0.05); meanwhile, the TC content of the composition is remarkably reduced (P is less than 0.05), and the TC content of the red yeast rice group and the composition group both have a reduction trend but are not remarkably changed. The results show that the red yeast rice, the Pu 'er tea and the composition can adjust the blood lipid abnormality of the NAFLD rat, and the effect of the composition is obviously superior to that of the red yeast rice or the Pu' er tea.
(III) influence of composition, red yeast rice and Pu' er tea on organ index of rat with high fat induction NAFLD
After 12 weeks of experiment, the liver, kidney and spleen of each group of rats were weighed, and the liver index, spleen index and kidney index of each group were calculated (table 5). The results show that the kidney index and the spleen index of the other administration groups except the spleen index of the monascus group have no significant difference (P is less than 0.05) compared with the normal group, and the experimental method has no significant damage to the kidney and the spleen of the rat. Compared with the normal group, the liver index difference of other groups is obvious (P is less than 0.05, P is less than 0.01, and P is less than 0.001), which indicates that after NAFLD rats are induced by high fat for 12 weeks, the liver is enlarged and damaged; compared with the model group, the liver index of each administration group is reduced, the composition group is obviously reduced, and the red yeast rice group and the Pu' er tea group have no obvious difference, which shows that the composition can obviously inhibit the high fat induced liver injury of NAFLD rats.
TABLE 5 Effect of the compositions, Red Rice and Pu her tea on the visceral index of NAFLD rats: (
Figure BDA0002502419200000121
n＝7)
Figure BDA0002502419200000122
(IV) influence of composition, red yeast rice and Pu' er tea on liver histomorphology of rat subjected to high fat induction of NAFLD
The histomorphometric results of the liver of rats in each group showed (fig. 13) that the percentage of lipid droplets in the normal group rats was 4.27%, the percentage of lipid droplets in the model group was 55.47%, the percentage of resveratrol was 38.68%, and the percentage of lipid droplets in the red yeast rice, pu' er tea and composition groups was 45.17%, 42.02% and 35.94%. The rats in the model group show diffuse hepatocellular edema degeneration, are scattered in a large number of round vacuolated lipid droplets with different sizes and inflammatory cell infiltration in the sink area. The pathological morphology of the liver of the rats interfered by the resveratrol group and the administration group is close to that of the normal control group, a small amount of inflammatory cells infiltrate, and the number of lipid drops is less than that of the model group. The results show that the red yeast rice, the Pu 'er tea and the composition extract can effectively improve the liver histomorphosis of a rat subjected to high fat induction of NAFLD, and the effect of the composition extract is better than that of the red yeast rice or the Pu' er tea extract.
The immunohistochemical Tunel apoptosis rate analysis result (figure 14) shows that the liver cell apoptosis rates of the normal group, the model group, the resveratrol group, the monascus group, the Pu 'er tea group and the composition group are respectively 19.76%, 35.00%, 6.23%, 11.45%, 47.98% and 11.87%, which indicates that the three extracts can relieve cell apoptosis in the NAFLD process and protect liver cells from damage, and the composition and the monascus effect are superior to that of the Pu' er tea.
(V) influence of composition, red yeast rice and Pu' er tea on TG, TC, LDL-C and HDL-C of liver of NAFLD rat
The results in FIG. 15 show that compared with the normal group, the liver tissues of the model group have significantly increased TC, TG and LDL-C contents (P <0.01, P <0.001), and the HDL-C content has a descending trend but no significant difference, indicating that the liver of the high-fat-induced NAFLD rat has obvious lipid metabolism disorder. Compared with a model group, TC, TG and LDL-C in the resveratrol group liver tissue have significant difference (P is less than 0.05, P is less than 0.01, and P is less than 0.001), which shows that the resveratrol group liver lipid abnormality of a rat NAFLD induced by high fat can be regulated; after different extracts are given, the TC and TG contents in the monascus group, the Pu' er tea group and the composition group are obviously reduced (P is less than 0.01 and P is less than 0.001), the LDL-C content in the monascus group and the composition group is obviously reduced (P is less than 0.05), and the HDL-C in the three extract administration groups has the rising and lowering tendency but has no obvious difference; compared with the composition group, the TC of the monascus group and the Pu' er tea group is remarkably increased (P is less than 0.05), and TG also has a tendency to be increased. The results show that the three extracts can better improve the high fat induced liver lipid abnormality of the NAFLD rat, and the effect of the composition group is obviously better than that of the monascus group or the Pu' er tea group.
(VI) the influence of the composition, red yeast rice and Pu' er tea on MDA and GSH-PX in liver of NAFLD rat
As shown in the results of FIG. 16, the GSH-PX activity in the liver of the model group rat is remarkably reduced (P <0.001) and the MDA content is remarkably increased (P <0.001) compared with the liver of the normal group, which indicates that the liver of the NAFLD rat has oxidative stress and lipid peroxidation injury. Compared with a model group, the resveratrol group GSH-PX has obviously improved activity (P is less than 0.05) and obviously reduced MDA content (P is less than 0.01), which shows that resveratrol can reduce the oxidative stress and lipid peroxidation injury of the liver of a NAFLD rat; compared with a model group, the activity of GSH-PX in the composition group is obviously improved (P is less than 0.001), the red yeast rice group and the Pu' er tea group have the increasing trend but have no obvious difference, and simultaneously, the MDA content of the three extracts is obviously reduced (P is less than 0.05, P is less than 0.01, and P is less than 0.001); compared with the composition group, the activity of the GSH-PX in the Pu 'er tea group is obviously reduced, the red yeast rice group also has a reduction trend, but no obvious difference exists, and simultaneously, the MDA content of the Pu' er tea and the red yeast rice group is obviously increased (P is less than 0.05 and P is less than 0.01). The results show that the three extracts can regulate the oxidative stress and lipid peroxidation injury of the liver of a rat NAFLD, so that the occurrence of non-alcoholic fatty liver is relieved, and the effect of the composition is obviously superior to that of red yeast rice and Pu' er tea.
(V) influence of the composition, red yeast rice and Pu' er tea on ATP synthase, complexI and complexII in liver mitochondria of NAFLD rats as shown in the result of figure 17, compared with the normal group, the activities of the ComplexI, ComplexII and ATP synthase (Na + -K + -ATP ase, Ca2+ -Mg2+ -ATP ase) in liver mitochondria of model groups of rats are obviously reduced (P is less than 0.01, P is less than 0.001), which indicates that high fat induces energy metabolism disorder of liver mitochondria of NAFLD rats. Compared with a model group, the enzyme activities of Na + -K + -ATP ase and complexII enzyme in the resveratrol administration group are significantly different (P is less than 0.05 and P is less than 0.01), the enzyme activities of Ca2+ -Mg2+ -ATP ase and complexI enzyme are improved to a certain extent, but the significant difference is not generated, which shows that the enzyme activities can improve the energy metabolism abnormality of liver mitochondria of NAFLD rats to a certain extent.
Compared with a model group, after different extracts are given, the activities of ATP synthase (Na + -K + -ATP ase, Ca2+ -Mg2+ -ATP ase) in liver mitochondria of a Pu 'er tea group and a composition group are obviously improved (P is less than 0.05, P is less than 0.01, and P is less than 0.001), the activities of ATP synthase in liver mitochondria of a red yeast rice group are also improved, but have no obvious difference, meanwhile, the activities of ComplexI and II enzyme of the composition group are obviously improved (P is less than 0.01), and the activities of ComplexI and II enzyme of the red yeast rice group and the Pu' er tea group are improved, but have no obvious difference; compared with the composition group, the activity of ATP synthase (Na + -K + -ATP ase, Ca2+ -Mg2+ -ATP ase) and the activity of ComplexI enzyme in the Pu' er tea group are obviously reduced (P is less than 0.05, and P is less than 0.01); the activities of the red yeast ATP synthase and the enzymes of complete I and II are reduced, but no significant difference exists. The results show that the three extracts can regulate the energy metabolism disorder of liver mitochondria of NAFLD rats to a certain extent, and the drug effect of the composition is obviously superior to that of red yeast rice or Pu' er tea.

Claims (10)

1. A health tea for preventing lipid metabolism disorder comprises the following raw materials: 1-20g of rhizoma polygonati, 1-20g of angelica, 1-20g of pseudo-ginseng, 1-10g of elecampane, 1-10g of poria cocos, 1-10g of red yeast rice and 1-20g of Pu' er tea.
2. The health tea of claim 1, consisting of the following raw materials: 1-10g of rhizoma polygonati, 1-10g of angelica, 1-10g of pseudo-ginseng, 1-5g of elecampane, 1-5g of poria cocos, 1-5g of red yeast rice and 1-10g of Pu' er tea.
3. The health tea of claim 1, consisting of the following raw materials: 1-5g of rhizoma polygonati, 1-5g of angelica, 1-5g of pseudo-ginseng, 1-4g of elecampane, 1-4g of poria cocos, 1-4g of red yeast rice and 1-5g of Pu' er tea.
4. The health tea of claim 1, consisting of the following raw materials: 2-4g of rhizoma polygonati, 2-4g of angelica, 2-4g of pseudo-ginseng, 1-3g of elecampane, 1-3g of poria cocos, 1-3g of red yeast rice and 2-4g of Pu' er tea.
5. The health tea of claim 1, consisting of the following raw materials: 3g of rhizoma polygonati, 3g of angelica, 3g of pseudo-ginseng, 2g of elecampane, 2g of poria cocos, 2g of red yeast rice and 3g of Pu' er tea.
6. A composition for preventing and treating lipid metabolism disorder comprises the following raw materials: 1-20g of rhizoma polygonati, 1-20g of angelica, 1-20g of pseudo-ginseng, 1-10g of elecampane, 1-10g of poria cocos, 1-10g of red yeast rice and 1-20g of Pu' er tea.
7. The composition of claim 6, wherein: the dosage form is selected from decoction, tablet, capsule, pill, dripping pill, granule, and powder.
8. The composition of claim 6, wherein the extraction process comprises the steps of: pulverizing the raw materials into fine powder, reflux-extracting with 12 times of 95% ethanol at 90 deg.C, reflux-extracting with 12 times of 70% ethanol for 2 hr each time, mixing the extractive solutions, concentrating at 65 deg.C and 100 deg.C under reduced pressure, recovering ethanol, and making into lyophilized powder.
9. Use of a composition according to any one of claims 6 to 8 for the preparation of a medicament for the prevention and treatment of abnormal lipid metabolism.
10. Use of the health tea of any one of claims 1 to 5 for the preparation of a health product for preventing abnormal lipid metabolism.
CN202010436353.1A 2020-05-21 2020-05-21 Composition for preventing and treating lipid metabolism disorder Active CN111513155B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010436353.1A CN111513155B (en) 2020-05-21 2020-05-21 Composition for preventing and treating lipid metabolism disorder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010436353.1A CN111513155B (en) 2020-05-21 2020-05-21 Composition for preventing and treating lipid metabolism disorder

Publications (2)

Publication Number Publication Date
CN111513155A true CN111513155A (en) 2020-08-11
CN111513155B CN111513155B (en) 2022-11-08

Family

ID=71912479

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010436353.1A Active CN111513155B (en) 2020-05-21 2020-05-21 Composition for preventing and treating lipid metabolism disorder

Country Status (1)

Country Link
CN (1) CN111513155B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432376A (en) * 2020-11-05 2022-05-06 北京中医药大学 Blood fat regulating pharmaceutical composition and preparation thereof
CN116808097A (en) * 2023-06-30 2023-09-29 云南中医药大学 Euphorbia pekinensis extract with hypoglycemic activity and application thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101020041A (en) * 2007-03-28 2007-08-22 北京艺信堂医药研究所 Antilipemic health product
CN101342314A (en) * 2008-08-27 2009-01-14 江苏省中医院 Traditional Chinese medicine for treating cardiovascular disease, preparation method and uses thereof
CN101836725A (en) * 2010-01-01 2010-09-22 广东医学院 Application of red rice residue product in preparing health-care food for lowering blood fat
CN102613330A (en) * 2012-04-27 2012-08-01 西藏月王生物技术有限公司 Fermented red yeast tea and extract, extract composition and preparation method thereof
CN104013696A (en) * 2014-06-18 2014-09-03 上海中医药大学 Plant medicine composition for preventing and treating metabolic syndrome and application thereof
CN104288412A (en) * 2014-11-07 2015-01-21 河南中医学院 Traditional Chinese medicinal composition for treating metabolic syndrome
CA3019312A1 (en) * 2018-10-01 2019-01-23 Jk & Bestin Enterprise Ltd. Compositions for reducing blood lipid levels and methods for manufacturing thereof
CN109528884A (en) * 2019-01-29 2019-03-29 上海中医药大学附属曙光医院 It is a kind of regulate and control cholesterol metabolic Chinese medicine composition and its application

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101020041A (en) * 2007-03-28 2007-08-22 北京艺信堂医药研究所 Antilipemic health product
CN101342314A (en) * 2008-08-27 2009-01-14 江苏省中医院 Traditional Chinese medicine for treating cardiovascular disease, preparation method and uses thereof
CN101836725A (en) * 2010-01-01 2010-09-22 广东医学院 Application of red rice residue product in preparing health-care food for lowering blood fat
CN102613330A (en) * 2012-04-27 2012-08-01 西藏月王生物技术有限公司 Fermented red yeast tea and extract, extract composition and preparation method thereof
CN104013696A (en) * 2014-06-18 2014-09-03 上海中医药大学 Plant medicine composition for preventing and treating metabolic syndrome and application thereof
CN104288412A (en) * 2014-11-07 2015-01-21 河南中医学院 Traditional Chinese medicinal composition for treating metabolic syndrome
CA3019312A1 (en) * 2018-10-01 2019-01-23 Jk & Bestin Enterprise Ltd. Compositions for reducing blood lipid levels and methods for manufacturing thereof
CN109528884A (en) * 2019-01-29 2019-03-29 上海中医药大学附属曙光医院 It is a kind of regulate and control cholesterol metabolic Chinese medicine composition and its application

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
晋玉梅: "通络调脂汤治疗血脂异常", 《中国民间疗法》 *
梁慧莉等: "红曲三七姜黄复配对高脂血症模型饮食大鼠血脂的影响", 《广西医科大学学报》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432376A (en) * 2020-11-05 2022-05-06 北京中医药大学 Blood fat regulating pharmaceutical composition and preparation thereof
CN116808097A (en) * 2023-06-30 2023-09-29 云南中医药大学 Euphorbia pekinensis extract with hypoglycemic activity and application thereof
CN116808097B (en) * 2023-06-30 2024-02-20 云南中医药大学 Euphorbia pekinensis extract with hypoglycemic activity and application thereof

Also Published As

Publication number Publication date
CN111513155B (en) 2022-11-08

Similar Documents

Publication Publication Date Title
CN111513155B (en) Composition for preventing and treating lipid metabolism disorder
CN116234561A (en) Pharmaceutical composition for preventing and treating respiratory diseases in winter
WO2010054470A1 (en) Pumpkin and rose hips weight loss composition
CN111803600A (en) Traditional Chinese medicine composition for preventing and treating non-alcoholic fatty liver disease and preparation method
TW201338786A (en) Pharmaceutical composition for preventing and treating liver fibrosis or nonalcoholic fatty liver disease
CN100427136C (en) Medicinal composition for treating fatty liver, its preparation and use
Chen et al. Toxicity studies of rhizoma polygonati odorati
CN108452009A (en) A kind of application including Common Leafflower Herb, rainbow conk, Radix Salviae Miltiorrhizae and the Chinese medicine composition of Asian puccoon in the drug for preparing treatment liver cancer
CN110876768A (en) Traditional Chinese medicine formula, preparation method and application for losing weight, reducing fat and reducing blood fat
CN109985079B (en) Preparation method and application of double-layer tablet containing ginseng and pseudo-ginseng flower
CN113288937B (en) Anti-inflammatory traditional Chinese medicine compound and preparation method and application thereof
CN103735621A (en) Chinese medicinal composition with blood lipid reducing and immunity enhancing effects
CN105520847B (en) A kind of heal-care essential oil and preparation method thereof containing JINHUAKUIZI oil
CN113662991A (en) Pharmaceutical composition for treating livestock and poultry diarrhea, preparation method and application thereof
CN103877323B (en) Medicinal composition for treating non-alcoholic fatty liver disease
KR101407188B1 (en) A composition comprising an extract of fermented or non-fermented combined crude drugs for treating and preventing abnormal metabolic diseases
CN110123824B (en) Ilicis Pubescentis saponin A1New use of
CN102793767B (en) Radix notoginseng pharmaceutical composition for treating insomnia as well as preparation method and application of pharmaceutical composition
CN112336764A (en) Traditional Chinese medicine composition for resisting oxidation and enhancing immunity and preparation method and application thereof
CN117100739B (en) Small molecule composition for negative regulation of Nrf2 signal path and application thereof
CN106942439B (en) Cyclocarya paliurus and guava leaf blood glucose reducing tea and preparation method and application thereof
CN117180340B (en) Composition for reducing blood fat and preparation method and application thereof
KR102559079B1 (en) Pharmaceutical composition for preventing or treating of cancer comprising medicinal herb complex extract
TWI501771B (en) Pharmaceutical composition for preventing and treating liver fibrosis
CN115487260B (en) Traditional Chinese medicine composition for treating hypercholesterolemia or atherosclerosis and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant